A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)

Sponsor
Bayer (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT05150938
Collaborator
Janssen Research & Development, LLC (Industry)
15,000
1
9.5
1585.3

Study Details

Study Description

Brief Summary

This is an observational study in which patient data from the past on venous thromboembolism (VTE) in patients with cancer is studied.

VTE is a condition in which a patient has problems due to the formation of blood clots in the veins. Blood clots can reduce the flow of blood to vital organs such as the heart and lungs, which can lead to them becoming damaged. VTE can also be "recurrent". This means that the blood clots have returned after treatment. People who have cancer have an increased risk of developing VTE.

Three main types of anticoagulation treatments ("blood thinners") have been available for patients with cancer who also have VTE

  • Low molecular weight heparins (LMWHs)

  • Vitamin K antagonists (VKAs)

  • Non-vitamin K antagonist oral anticoagulants (NOACs) The treatment rivaroxaban belongs to the NOACs.

Compared to other treatments available to patients who have cancer and VTE, NOACs may cause fewer medical problems and can be easier for patients to take correctly.

In this study, the researchers will collect data about:
  • the type of VTE treatments given and for how long the treatments are taken

  • the risk of blood clots returning in the veins after treatment, any events of major bleeding, and the number of deaths in patients with cancer who do not have a high risk of bleeding

The researchers will compare this information in the patients

  • who received rivaroxaban to the patients who received LMWHs

  • who received NOACs to the patients who received LMWHs.

There will be no required visits with a study doctor or required tests in this study. The researchers will look at the health information from adult patients in Sweden who were diagnosed with cancer between 2013 and 2019 and also have VTE. The researchers will collect this information from Swedish health registers including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

Condition or Disease Intervention/Treatment Phase
  • Drug: Rivaroxaban (Xarelto, BAY59-7939)
  • Drug: Low molecular weight heparin (LMWH)
  • Drug: vitamin K antagonist (VKA)
  • Drug: other NOACs

Study Design

Study Type:
Observational
Anticipated Enrollment :
15000 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban in SwEden (OSCAR-SE)
Actual Study Start Date :
Mar 18, 2022
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Cancer patients with VTE

Cancer patients who received anticoagulation treatment.

Drug: Rivaroxaban (Xarelto, BAY59-7939)
Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

Drug: Low molecular weight heparin (LMWH)
Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

Drug: vitamin K antagonist (VKA)
Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

Drug: other NOACs
Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

Outcome Measures

Primary Outcome Measures

  1. Recurrence of VTE [Retrospective data analysis from 2013 to 2020]

  2. Major bleedings [Retrospective data analysis from 2013 to 2020]

  3. All-cause death [Retrospective data analysis from 2013 to 2020]

  4. Choice of anticoagulation treatments for VTE [Retrospective data analysis from 2013 to 2020]

  5. Duration of anticoagulation treatments for VTE [Retrospective data analysis from 2013 to 2020]

  6. Recurrence of VTE with different treatment types of LMWH, VKA and NOAC [Retrospective data analysis from 2013 to 2020]

  7. Major bleedings with different treatment types of LMWH, VKA and NOAC [Retrospective data analysis from 2013 to 2020]

  8. All-cause death with different treatment types of LMWH, VKA and NOAC [Retrospective data analysis from 2013 to 2020]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • A resident in Sweden of 18+ years of age

  • A Swedish Person Identification Number

  • A diagnosis of cancer ((ICD10 = C00-C97) in the Swedish Cancer registry during 2013-2019 and a diagnosis of VTE subsequent to the cancer diagnosis.

Exclusion Criteria:
  • A diagnosis of atrial fibrillation, total hip or knee replacement or acute coronary syndrome (for evaluation of treatment patterns) before the date of VTE diagnosis

  • A dispensed prescription for any oral anticoagulant (OAC) before the date of VTE diagnosis

  • A cancer diagnosis associated with high bleeding risk

Contacts and Locations

Locations

Site City State Country Postal Code
1 Swedish registries Multiple Locations Many Locations Sweden

Sponsors and Collaborators

  • Bayer
  • Janssen Research & Development, LLC

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Bayer
ClinicalTrials.gov Identifier:
NCT05150938
Other Study ID Numbers:
  • 21616
First Posted:
Dec 9, 2021
Last Update Posted:
Aug 19, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 19, 2022